| h-41b54533e6 | A lower-dose 50-100 mg/day glial anti-inflammatory effect may occur, but is unli | 0.48 | 0.34 | IL6; TGFB1; AIF1; MAPK14; MAPK8; NFKB1 | proposed | 2026-04-25 | |
| h-896e71b129 | Platelet-Derived PDGF-BB Primes VSMCs for P2RY12 Upregulation | 0.48 | 0.42 | PDGFB, PDGFRB | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-041434-a4d6154a |
| h-cb2065e26c | ISG Threshold Model Explains Acute vs Chronic Neurodegeneration Outcomes | 0.48 | 0.42 | USP18 / JAK/STAT pathway | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-062141-fc60e018 |
| h-39c4d643 | FUS-ALS-Specific Ferroptosis Vulnerability Through NCOA4-Mediated Ferritinophagy | 0.48 | 0.48 | NCOA4 | proposed | 2026-04-16 | SDA-2026-04-16-gap-ferroptosis-als-d2fb6bf796ed |
| h-2e7eb2ea | Enteric Nervous System Prion-Like Propagation Blockade | 0.48 | 0.50 | TLR4, SNCA | archived | 2026-04-02 | SDA-2026-04-01-gap-20260401-225155 |
| h-5f3db142c9 | CX3CR1 PET with Nano-bodies for Microglial Surveillance State Mapping | 0.48 | 0.40 | CX3CR1 | proposed | 2026-04-22 | SDA-2026-04-06-gap-debate-20260406-062039-3b945972 |
| h-826df660 | Optogenetic Control of Mitochondrial Transfer Networks | 0.48 | 0.40 | ChR2 | archived | 2026-04-02 | SDA-2026-04-01-gap-20260401231108 |
| h-SDA-2026-04-26-gap | Nuclear Export Sequestration and Cytoplasmic Depletion | 0.48 | 0.38 | NXF1 (TAP), THOC4 (AlyREF), DDX39B (UAP56); PHAX | proposed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260412-094853-199f4f1b |
| h-SDA-2026-04-26-gap | Amyloid Plaque Clearance Triggers Downstream Reduction in Tau Kinase Activity, N | 0.48 | 0.27 | GSK3B, CDK5 | proposed | 2026-04-26 | SDA-2026-04-26-gap-debate-20260417-033134-20519caa |
| h-d7b7189f | Ferroptosis as Context-Dependent and Motor Neuron-Subtype Selective | 0.47 | 0.25 | | proposed | 2026-04-18 | SDA-2026-04-18-gap-debate-20260417-032952-48bdcbea |
| h-fe39641b | CHIP E3 Ligase Enhancement to Target Synaptic Proteins for Degradation | 0.47 | 0.47 | CHIP/STUB1 (STIP1 homology and U-box containing protein 1) | proposed | 2026-04-25 | SDA-2026-04-16-frontier-proteomics-1c3dba72 |
| h-fdc381dee7 | Cerebral VSMC foam cells induce pericyte detachment via PDGF-BB/VEGF imbalance, | 0.47 | 0.50 | P2RY12 | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-041434-d7920f3b |
| h-var-afbf2de722 | VPS26A Subunit Enhancement to Stabilize Retromer Complex Assembly | 0.47 | 0.26 | VPS26A | proposed | 2026-04-26 | SDA-2026-04-16-frontier-proteomics-1c3dba72 |
| h-f3593d42c8 | Glial Progenitor Cell Support in Huntington's Disease | 0.47 | 0.42 | HTT | proposed | 2026-05-06 | SDA-2026-05-06-gap-test-20260425-224949 |
| h-f8b19743a2 | Moderate hyperoxia (1.5-2.0 ATA) optimally stabilizes HIF-1α to enhance VEGF-med | 0.47 | 0.48 | HIF1A | proposed | 2026-04-25 | SDA-2026-04-26-gap-pubmed-20260410-181340-8acb24dc-debate |
| h-1d3f23017e | APOE4-associated inflammatory signaling amplifies SREBP2 activity in glia indepe | 0.47 | 0.46 | SREBF2 | proposed | 2026-04-24 | SDA-2026-04-25-gapdebate-f4c8357045 |
| h-e8569f838f | CD44-Mediated Src/PI3K/Akt Signaling Cascade | 0.47 | 0.55 | CD44, SRC, PI3K p85 (PIK3R1), MTOR | proposed | 2026-04-22 | SDA-2026-04-06-gap-pubmed-20260406-062118-e3613755 |
| h-286c496d01 | Mitochondrial Dysfunction Increasing Neuronal Vulnerability to TDP-43 Toxicity | 0.47 | 0.40 | MCU, CK1D, CSNK2A1, GSK3B, PARP1 | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-062202-c8c5a9a1 |
| h-85cbb5cb4d | C1Q-Glia Cross-Talk in Vascular Dementia Pathogenesis | 0.47 | 0.40 | C1QA/C1QC | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-062122-b65f8ebc |
| h-2e7fe1f16a | Lysosomal Accumulation-Induced V-ATPase Inhibition (Osmotic Trapping) | 0.47 | 0.55 | ATP6V0C, ATP6V1 subunits (V-ATPase complex) | proposed | 2026-04-21 | SDA-2026-04-08-gap-pubmed-20260406-062150-5b7d1556 |
| h-8bd89d90 | Prohibitin-2 Mitochondrial Cross-Seeding Hub Disruption | 0.47 | 0.45 | PHB2 | archived | 2026-04-02 | SDA-2026-04-01-gap-9137255b |
| h-aging-h3-apoe-trem | APOE and TREM2 interact to modulate age-dependent microglial dysfunction | 0.47 | 0.72 | TREM2 | open | 2026-04-23 | aging-mouse-brain-2026-04-02 |
| h-c3354d65 | Cross-Tissue Communication Disruption | 0.47 | 0.41 | MULTIPLE | proposed | 2026-04-16 | SDA-2026-04-16-gap-bbb-tjp-20260416041707 |
| h-SDA-2026-04-26-gap | Sub-antidepressant Doses Suppress NLRP3 Inflammasome via P2X7 Receptor Blockade | 0.47 | 0.38 | P2RX7 (P2X7 receptor), NLRP3 inflammasome, IL-1beta | proposed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260411-081101-dfe3eacb |
| h-7693c291 | RNA-Binding Competition Therapy for TDP-43 Cross-Seeding | 0.47 | 0.40 | TARDBP | archived | 2026-04-02 | SDA-2026-04-01-gap-9137255b |
| h-var-387b2bc276 | Gamma-Entrained PV Interneurons Enable Precision p-tau217-Guided lncRNA Exosome | 0.46 | 0.35 | PVALB, lncRNA-0021 | promoted | 2026-04-21 | SDA-2026-04-26-gap-pubmed-20260410-150509-76c40dac-debate |
| h-f90320704e | TYROBP Network Hyperactivation Marks Point of No Return | 0.46 | 0.42 | TYROBP/SYK axis, MAPK/ERK signaling | proposed | 2026-04-22 | SDA-2026-04-06-gap-debate-20260406-062045-7a6cf14e |
| h-d504707b4e | Microglial Priming Window for HDAC1-Dependent DAM Transition | 0.46 | 0.52 | HDAC1 | proposed | 2026-04-21 | SDA-2026-04-07-gap-debate-20260406-062039-7ef9980b |
| h-d94e17c018 | Liquid-Liquid Phase Separation (LLPS) Saturation Partitioning Excludes Autophagy | 0.46 | 0.38 | SQSTM1/CALCOCO2 | proposed | 2026-04-21 | SDA-2026-04-08-gap-pubmed-20260406-041423-9c2c2ee3 |
| h-868a4e91eb | Nuclear Pore Complex Integrity as Proteostasis Checkpoint Failure | 0.46 | 0.48 | RANBP2/Nup358, importin-β | proposed | 2026-05-03 | SDA-2026-05-03-gap-test-20260425-224949 |
| h-629ae6fdc0 | circRNA dysregulation as neurodegeneration biomarker and exploratory therapeutic | 0.46 | 0.42 | circHomer1; circCfl1; ALKBH5; YTHDF2 | proposed | 2026-04-30 | SDA-2026-04-30-gap-test-20260425-224949 |
| h-3f193704f2 | EC-II SST→PV Disinhibition Circuit Mechanism (Preclinical-Only Exploration) | 0.46 | 0.48 | GABAₐα5 subunit; PV+ basket cell network | proposed | 2026-04-28 | SRB-2026-04-28-h-var-b7e4505525 |
| h-e031e9fde6 | HBOT at 1.5 ATA for 90 days restores BBB integrity by upregulating claudin-5 and | 0.46 | 0.45 | CLDN5 | proposed | 2026-04-25 | SDA-2026-04-26-gap-pubmed-20260410-181340-8acb24dc-debate |
| h-a0c62d04e6 | BIN1-dependent trafficking defects determine whether post-Aβ tau missorting reso | 0.46 | 0.39 | BIN1,MAPT | proposed | 2026-04-25 | SDA-2026-04-25-gapdebate-98a600b3ed |
| h-342754e5ef | TSPO-Mediated TDP-43 Mitochondrial Import | 0.46 | 0.42 | TSPO (TSPO), TDP-43-TSPO protein-protein interaction | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-062141-611cf046 |
| h-0d3b8d6197 | Necroptosis-cGAS Feedforward Loop Converts TDP-43 Pathology into Neuroinflammati | 0.46 | 0.38 | MLKL / RIPK1 | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-062141-fc60e018 |
| h-b17969bbb7 | DNMT3A-Mediated de novo Methylation Corrects 'Epigenetic Scars' at Polycomb Targ | 0.46 | 0.50 | DNMT3A | proposed | 2026-04-21 | SDA-2026-04-10-gap-20260410-091440 |
| h-var-b52ba047a5 | Mitochondrial Dysfunction in Neurodegeneration | 0.46 | 0.30 | NDUFV1 | archived | 2026-04-21 | |
| h-var-adc924c2d4 | Alpha-Beta Oscillation Coupling Enhances lncRNA-9969-Mediated Autophagy Through | 0.46 | 0.33 | SST, CREB1, lncRNA-9969, neuronal autophagy pathway | proposed | 2026-04-21 | SDA-2026-04-26-gap-pubmed-20260410-150509-76c40dac-debate |
| h-var-c4c7aca6dc | ACSL4-Mediated Neuroinflammatory Amplification in Disease-Associated Microglia | 0.46 | 0.71 | ACSL4 | promoted | 2026-04-26 | SDA-2026-04-03-gap-seaad-v4-20260402065846 |
| h-40d0524f | Restoration of Neuronal Ketone Body Utilization via MCT1 Upregulation | 0.46 | 0.55 | SLC16A1 (MCT1) | proposed | 2026-04-25 | SDA-2026-04-16-frontier-metabolomics-f03b09d9 |
| h-var-2277d00a32 | Astrocytic SPP1 Modulation via STAT3-Dependent Transcriptional Control | 0.46 | 0.36 | SPP1 | superseded | 2026-04-21 | SDA-2026-04-15-gap-pubmed-20260406-062118-e3613755 |
| SDA-2026-04-16-hyp-f | Selective Microglial Senescence Targeting via TREM2 Modulation | 0.46 | 0.29 | TREM2 | proposed | 2026-04-16 | SDA-2026-04-04-gap-senescent-clearance-neuro |
| h-fdda39f6 | CX3CL1 Mimetic Peptide to Disrupt Fractalkine Signaling Dysregulation | 0.46 | 0.45 | CX3CL1/CX3CR1 axis; target: CX3CR1 receptor activation | proposed | 2026-04-25 | SDA-2026-04-16-frontier-immunomics-e6f97b29 |
| h-cc077b4f0d | Intranasal IGFBPL1 Delivery via Olfactory Pathway | 0.46 | 0.45 | IGFBPL1 | proposed | 2026-04-22 | SDA-2026-04-06-gap-debate-20260406-062045-6addd0cf |
| h-5d753df0 | Kinase Inhibitor-C1q Structural Convergence for Bifunctional Drug Design | 0.46 | 0.30 | C1QA/C1QB/C1QC, ALK, SYK | proposed | 2026-04-16 | SDA-2026-04-16-gap-pubmed-20260410-095709-4e97c09e |
| h-46e028b6 | Selective OGA Inhibition as 'Tau Stabilization' Strategy Without Phosphorylation | 0.46 | 0.42 | MGEA5 (OGA) | proposed | 2026-04-13 | SDA-2026-04-13-gap-debate-20260412-094612-a2e3bd09 |
| h-var-c261b9d0cd | CSF Neurofilament Light Chain-Guided Astrocyte-Derived Extracellular Vesicle Del | 0.46 | 0.36 | CSF neurofilament light chain (NfL), lncRNA-0021, astrocyte- | promoted | 2026-04-21 | SDA-2026-04-26-gap-pubmed-20260410-150509-76c40dac-debate |
| hyp-SDA-2026-04-09-g | Glycan-Disrupting Tau Disaggregation | 0.46 | 0.50 | NEU1 | active | 2026-04-27 | SDA-2026-04-09-gap-debate-20260409-201742-d279750b |
| hyp-SDA-2026-04-09-g | Competitive Glycan Decoys for Tau Vesicle Neutralization | 0.46 | 0.50 | MAPT | active | 2026-04-27 | SDA-2026-04-09-gap-debate-20260409-201742-d279750b |